e-learning
resources
London 2016
Wednesday, 07.09.2016
IPF treatment II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Significant improvement in refractory chronic cough with inhaled PA101 in patients with idiopathic pulmonary fibrosis: Results from phase 2 trial
Ahmet Tutuncu (San Diego, United States of America), Surinder Birring, Marlies Wijsenbeek, Sanjay Agrawal, Ahmet Tutuncu, Alyn Morice
Source:
International Congress 2016 – IPF treatment II
Session:
IPF treatment II
Session type:
Oral Presentation
Number:
4958
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ahmet Tutuncu (San Diego, United States of America), Surinder Birring, Marlies Wijsenbeek, Sanjay Agrawal, Ahmet Tutuncu, Alyn Morice. LATE-BREAKING ABSTRACT: Significant improvement in refractory chronic cough with inhaled PA101 in patients with idiopathic pulmonary fibrosis: Results from phase 2 trial. Eur Respir J 2016; 48: Suppl. 60, 4958
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Source: Eur Respir J, 49 (5) 1601339; 10.1183/13993003.01339-2016
Year: 2017
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Year: 2017
Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
Source: Eur Respir J 2015; 46: 512-520
Year: 2015
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Acute exacerbation of idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 23: 792
Year: 2004
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020
Year: 2020
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Cough in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2016; 25: 278-286
Year: 2016
Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Late-breaking abstract: Pathological analysis of acute exacerbation of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept